Fintepla (fenfluramine) successfully managed the severe and difficult-to-treat seizures of a 20-year-old woman with Dravet syndrome, demonstrating the…
Articles by Forest Ray PhD
Caregivers of children with Dravet syndrome who are taking Fintepla (fenfluramine) report sustained seizure reductions and quality-of-life improvements,…
The risk of severe COVID-19 outcomes does not appear to increase in people with Dravet syndrome, although they still…
The two COVID-19 vaccines that recently received emergency approval from the U.S. and other worldwide regulatory agencies are expected…
The U.S. Food and Drug Administration (FDA) will allow an additional higher dose of STK-001 to be added…
The first patient has been successfully dosed in a Phase 2 clinical trial testing Epigenix Therapeutics’ EPX-100 (clemizole) as…
Fintepla — low-dose oral fenfluramine — moved one step closer to European approval, following a favorable opinion on its…
The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency (EMA), recommended lowering the…
Same But Different, a U.K. nonprofit that uses the arts to bring communities together, is holding a calendar photography…
Raremark, an online rare disease patient community, has launched a digital platform called Xperiome, aimed at streamlining the…